Target Company Overview
Darling Ingredients Inc. (NYSE: DAR) and Tessenderlo Group (XBRU: TESB) have announced the formation of a new joint venture, Nextida™, to merge their collagen and gelatin business segments. This strategic partnership aims to create a robust company focused on collagen-based health, wellness, and nutrition products, capitalizing on the rapidly growing global collagen market.
Nextida™ will be primarily owned by Darling Ingredients, which will hold 85% of the new entity while Tessenderlo Group retains the remaining 15%. This non-cash transaction combines the businesses of Darling's Rousselot and Tessenderlo's PB Leiner, initially targeting an annual revenue of approximately $1.5 billion with a combined production capacity of 200,000 metric tons across 23 facilities spanning South America, North America, Europe, and Asia.
Industry Overview in the Collagen Sector
The collagen market has demonstrated a significant upward trajectory over the past several years, driven largely by increasing consumer demand for health and wellness products. Collagen supplements and ingredients have become highly sought after for their purported health benefits, including improved skin elasticity, joint health, and overall vitality. As a result, the industry has witnessed substantial growth and innovation, establishing collagen as a valuable asset across various sectors.
In recent years, the health and wellness segment has expanded remarkably, with brands increasingly integrating collagen into formulations ranging from dietary supplements to beauty products. This surge can be attributed to a growing awareness of wellness and beauty routines among consumers, coupled with an emphasis on natural and sustainable ingredients, which align well with collagen’s sourcing and production processes.
Moreover, the food and pharmaceutical sectors are capitalizing on these trends, leveraging collagen's versatility and nutritional properties in developing new products. As companies aim to diversify their offerings and meet consumer demands for functional ingredients, the market for collagen is expected to continue its robust growth, positioning firms like Nextida to benefit significantly.
The regulatory landscape for collagen products is also evolving, with increased scrutiny and standards, driving demand for high-quality output from established players. As the market matures, companies that can navigate these regulations effectively will likely gain a competitive edge, highlighting the strategic significance of the Darling and Tessenderlo collaboration.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Rationale Behind the Deal
The collaboration between Darling Ingredients and Tessenderlo Group is founded on a shared vision of enhancing their market positions within the growing collagen segment. By consolidating their capabilities and resources, the companies expect to unlock substantial synergies that will accelerate product development and enhance operational efficiencies.
Furthermore, the merger provides a strong platform for innovation in product offerings, enabling Nextida to meet the increasing demand for collagen-based health products. By focusing on expanding their product portfolio and leveraging each other's strengths, both companies are strategically positioned to maximize shareholder value and capture a larger share of the market.
Investor Background
Darling Ingredients Inc. is a leader in sustainable ingredient solutions, specializing in transforming by-products from the food and animal agriculture industries into high-value products. With operations in over 15 countries, it processes around 15% of global animal agricultural by-products and is a major producer of collagen and renewable energy. The company’s commitment to circular practices and innovative solutions solidifies its position as a key player in the collagen market.
Tessenderlo Group is an innovative industrial group based in Belgium, with a diverse focus on agriculture and bio-residual valorization, among other sectors. Active in more than 100 countries, the group employs a global workforce of over 7,000 and emphasizes the development of technology-driven solutions. Their collaboration with Darling Ingredients showcases a shared commitment to growth and innovation within the health and nutrition industries.
View of Dealert
This merger is expected to result in a significant enhancement of both companies’ market positions within the collagen sector. By pooling their resources and expertise, Darling Ingredients and Tessenderlo Group are poised to capitalize on the expanding demand for collagen-based products. The strategic focus on product development and operational synergies further strengthens the rationale behind the deal.
However, potential investors should remain cautious, as successful integration and execution of the planned strategies will be critical in realizing anticipated synergies and growth. Regulatory approvals and market response will play pivotal roles in determining the deal's long-term success.
The anticipated creation of Nextida represents an opportunity for both companies to enhance shareholder value substantially. As the demand for collagen continues to rise, the new entity could emerge as a leader in the sector, effectively meeting consumer demands while driving profit growth.
In conclusion, this merger aligns with prevailing trends in the health and wellness market, positioning Nextida to capture a share of the rapidly growing collagen market. Provided the integration is executed efficiently, it could indeed be a commendable investment for both Darling Ingredients and Tessenderlo Group.
Similar Deals
Kaiser Permanente → Renown Health
2026
Quest Diagnostics → Corewell Health
2025
Bain Capital and Evergreen Medical Properties → 122,000 square-foot medical outpatient facility
2025
InnovAge → Tampa General Hospital
2025
Community Health Network → Lifepoint Behavioral Health
2025
HealthStar Partners → Elanco Campus
2024
CareSource → Lakeland Care, Inc.
2024
Emory Healthcare → Houston Healthcare
2024
BCBS Venture Partners and Arboretum Ventures → SonarMD
2023
Rethink Healthcare Real Estate → Emergency Hospital in Mansfield
2023
Darling Ingredients
invested in
Nextida
in 2025
in a Joint Venture deal
Disclosed details
Revenue: $1,500M